Acting Attorney General Todd Blanche has reclassified state-licensed medical marijuana from a Schedule I to a Schedule III drug, placing it alongside substances like some pain medications and testosterone. This change aligns with many state laws but does not legalize marijuana federally or for recreational use. The reclassification could lead to more research opportunities and ease some tax and regulatory burdens on the cannabis industry. President Donald Trump had previously announced plans to reclassify marijuana, though he did not intend to legalize it. This development is significant as it may expand patient access to treatments and help doctors make better-informed decisions.
QUESTION: How might reclassifying medical marijuana impact the future of medical treatments and research?
State-licensed medical marijuana reclassified as less dangerous drug
